SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Scynexis: Q2 Earnings Snapshot
Earnings Flash (SCYX) SCYNEXIS Posts Q2 Revenue $736,000
Express News | Scynexis Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Scynexis 2Q Loss/Shr 30c >SCYX
Express News | Scynexis Q2 Operating Expenses USD 9.973 Million
Express News | Scynexis Q2 Basic EPS USD -0.3
Express News | Scynexis Q2 Net Income USD -14.458 Million
Express News | Scynexis Q2 Product Revenue USD 736 Thousand
Scynexis | 10-Q: Q2 2024 Earnings Report
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $8
Maxim Group analyst Jason McCarthy maintains $Scynexis(SCYX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 26.4% and a
Promising Clinical and Financial Prospects for SCYNEXIS: A Comprehensive Buy Rating Analysis
Express News | Scynexis Inc - Cash Runway Exceeds Two Years
Express News | Scynexis : GSK Will Also Pay Mid-Single Digit to Mid-Teen Digit Tiered Royalties on Totality of Ibrexafungerp Sales Across All Indications
Express News | Scynexis Inc - Milestone Payment Triggered by Clinical Study Reports
Express News | Scynexis : Eligible for Additional $323 Million in Milestone Payments
Express News | Scynexis to Receive $10 Million Milestone Payment From GSK Triggered by Delivery of Completed Furi, Cares and Nature Clinical Study Reports